- Home
- BSX
as 05-09-2025 4:00pm EST
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
| Founded: | 1979 | Country: | United States |
| Employees: | N/A | City: | MARLBOROUGH |
| Market Cap: | 138.4B | IPO Year: | 1992 |
| Target Price: | $110.57 | AVG Volume (30 days): | 7.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 23 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.37 | EPS Growth: | 15.23 |
| 52 Week Low/High: | $71.88 - $107.17 | Next Earning Date: | 04-23-2025 |
| Revenue: | $17,554,000,000 | Revenue Growth: | 19.36% |
| Revenue Growth (this year): | 15.77% | Revenue Growth (next year): | 10.33% |
Stock Insider Trading Activity of Boston Scientific Corporation (BSX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sorenson John Bradley | BSX | EVP, Global Operations | May 2 '25 | Sell | $104.54 | 4,572 | $477,956.88 | 18,705 | |
| Mahoney Michael F | BSX | Chairman, President & CEO | May 1 '25 | Sell | $102.52 | 164,443 | $16,851,973.70 | 1,535,706 | |
| Brown Vance R | BSX | SVP, GC and Corp. Secretary | Apr 21 '25 | Sell | $95.09 | 4,826 | $458,904.34 | 36,193 | |
| Mahoney Michael F | BSX | Chairman, President & CEO | Apr 1 '25 | Sell | $100.01 | 164,442 | $16,445,071.54 | 1,535,706 | |
| Brown Vance R | BSX | SVP, GC and Corp. Secretary | Mar 21 '25 | Sell | $100.85 | 4,826 | $486,702.10 | 36,193 | |
| Woodworth Emily | BSX | SVP, Global Controller and CAO | Mar 3 '25 | Sell | $104.80 | 7,631 | $800,896.51 | 432 | |
| Woodworth Emily | BSX | SVP, Global Controller and CAO | Feb 28 '25 | Sell | $101.13 | 9,887 | $999,872.31 | 432 | |
| Mirviss Jeffrey B. | BSX | EVP&Pres, Periph Intervent | Feb 24 '25 | Sell | $104.13 | 7,363 | $766,920.75 | 25,766 | |
| Zane Ellen M | BSX | Director | Feb 24 '25 | Sell | $104.23 | 13,586 | $1,416,133.99 | 34,944 | |
| Brown Vance R | BSX | SVP, GC and Corp. Secretary | Feb 21 '25 | Sell | $104.64 | 4,826 | $504,992.64 | 36,193 |
Latest Boston Scientific Corporation News
BSX Breaking Stock News: Dive into BSX Ticker-Specific Updates for Smart Investing
Insider Monkey
15 hours ago
Why Boston Scientific Corporation (BSX) Is Among the Best Medical Device Stocks to Buy Now
GuruFocus.com
19 hours ago
Elutia Inc (ELUT) Q1 2025 Earnings Call Highlights: Strategic Growth and Challenges in Transition
Zacks
a day ago
QuidelOrtho Stock Gains Following Q1 Earnings Beat, Margins Expand
Zacks
a day ago
INGN Stock Gains Following Q1 Earnings Beat, Revenues Up Y/Y
Zacks
a day ago
XRAY Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down
Zacks
2 days ago
Here is What to Know Beyond Why Boston Scientific Corporation (BSX) is a Trending Stock
StockStory
2 days ago
Reflecting On Medical Devices & Supplies - Diversified Stocks’ Q1 Earnings: Abbott Laboratories (NYSE:ABT)
Zacks
2 days ago
Abbott Outpaces Peers Defying Tariff Woes: Is ABT Stock a Smart Buy?
Compare BSX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BSX Boston Scientific Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.